The definitive diagnosis of pheochromocytoma rests primarily on the demonstration of excessive catecholamine production, best achieved with a resting plasma catecholamine assay plus a total urinary metanephrine assay, since no single clinical sign or symptom is pathognomonic. This is best followed by magnetic resonance imaging (MRI) to locate the tumor. 
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s COMMON SIGNS AND SYMPTOMS

s BIOCHEMICAL TESTS
Biochemical testing, if done carefully, can establish the diagnosis in more than 95% of cases. Demonstration of resting plasma catecholamine (norepinephrine and epinephrine) levels greater than 2,000 pg/mL, urinary total metanephrine levels greater than 1.8 mg/24 hours, and urinary norepinephrine levels greater than 156 µg/24 hours suggests the diagnosis of pheochromocytoma.
Combining assays increases sensitivity
Because of the serious consequences of missing the diagnosis, a test with the lowest possible false-negative rate should be used. Currently, this means using the combination of a resting plasma catecholamine assay and a total urinary metanephrine assay, which has a falsenegative rate of 2.7%. Taken individually, plasma catecholamine and total urinary metanephrine assays have a false-negative rate of 7%, urinary norepinephrine and epinephrine assays a rate of 14%, and the urinary vanillylmandelic acid assay a rate of 41%.
Patients with plasma catecholamine levels between 1,000 and 2,000 pg/mL and urinary metanephrine levels between 1.3 and 1.8 mg/24 hours may have neurogenically mediated catecholamine release and will require a suppression test (eg, with oral clonidine). This will cause these levels to fall by about 50% from baseline in patients with neurogenically mediated catecholamine release, but not in patients with pheochromocytoma.
Patients who are highly suspected of having pheochromocytoma and who have plasma catecholamine levels of 1,000 pg/mL or less and urinary metanephrine levels of 1.3 mg/24 Q:What is the best diagnostic approach when pheochromocytoma is suspected?
A:
The diagnosis rests on proving catecholamine overproduction hours or less require a provocative test (eg, with glucagon injection). This will cause plasma catecholamines to rise by two and a half fold if pheochromocytoma is present. Blood pressure may or may not change.
Patients with overt symptoms and normal or slightly increased plasma catecholamine and 24-hour urinary metanephrine values are unlikely to have pheochromocytoma. On the other hand, some patients with pheochromocytoma may remain asymptomatic despite high plasma catecholamine and 24-hour urinary metanephrine values. Clinical judgment dictates whether other biochemical tests should be performed to confirm or rule out other conditions that mimic the disease.
s DIFFERENTIAL DIAGNOSIS
Other conditions in which both plasma catecholamine and urinary metanephrine levels may be elevated to a degree usually encountered in pheochromocytoma include:
• Acute clonidine withdrawal • Acute alcohol withdrawal • Vasodilator therapy with hydralazine or minoxidil • Acute myocardial ischemia or infarction • Acute cerebrovascular accident • Cocaine abuse • Severe congestive heart failure Intravenous dopamine, dopaminergic drugs, and acute hypoglycemia can produce significant elevations of plasma epinephrine (labetalol can increase levels for 7 to 10 days) Phenylpropanolamine abuse can increase levels of urinary metanephrines (assayed by high-performance liquid chromatography) but not of plasma catecholamines (assayed by the radioenzymatic technique).
However, patients should not undergo localization procedures unless pheochromocytoma has been confirmed by biochemical testing and other conditions that can increase catecholamine levels have been ruled out.
s CONFIRMING THE DIAGNOSIS
Once biochemical testing suggests pheochromocytoma, MRI is the next step. It provides the highest sensitivity of current imaging techniques. If MRI detects no tumor in the neck, chest, or pelvis, then metaiodobenzylguanidine (MIBG) scintigraphy should be used. In rare instances, the octreotide scan is positive when MIBG scintigraphy is negative. Arteriography and vena cava sampling for catecholamine concentrations are rarely indicated. Please be sure to include your full address, phone number, fax number, and e-mail address. Please write concisely, as space is limited. Letters may be edited for style and length. We cannot return materials sent. Submission of a letter constitutes permission for the Cleveland Clinic Journal of Medicine to publish it in various editions and forms.
